Your browser doesn't support javascript.
loading
Very rare case of Graves' disease with resistance to methimazole: a case report and literature review.
Mori, Yusaku; Hiromura, Munenori; Terasaki, Michishige; Kushima, Hideki; Ohara, Makoto; Fukui, Tomoyasu; Takahashi, Yasuyoshi; Yamagishi, Sho-Ichi.
Afiliación
  • Mori Y; Anti-glycation Research Section, Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Hiromura M; Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Terasaki M; Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Kushima H; Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Ohara M; Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Fukui T; Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Takahashi Y; Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Yamagishi SI; Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan.
J Int Med Res ; 49(3): 300060521996192, 2021 Mar.
Article en En | MEDLINE | ID: mdl-33682498
ABSTRACT

BACKGROUND:

Methimazole (MMI) is used to treat hyperthyroidism in Graves' disease. It is rare to encounter patients in whom hyperthyroidism cannot be controlled using high doses of MMI.Case presentation A 21-year-old woman was referred to our hospital because of MMI-resistant Graves' disease. Although her MMI dose had been increased to 120 mg/day, her serum thyroid hormone concentration was too high to be measured. Additional therapy with lithium carbonate, and then with dexamethasone and inorganic iodine, was initiated. After 14 days, the patient's serum thyroid hormone concentration normalized, while she was taking 150 mg/day MMI, 800 mg/day lithium carbonate, 6 mg/day dexamethasone and 306 mg/day inorganic iodine, and total thyroidectomy was then performed. The patient was discharged 8 days after the thyroidectomy and experienced no major complications.

CONCLUSIONS:

We have presented a rare case of Graves' disease that was resistant to high-dose MMI. Combination therapy of MMI with lithium carbonate, dexamethasone and inorganic iodine may represent a therapeutic option for the preoperative preparation of patients with MMI-resistant Graves' disease.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Graves / Metimazol Límite: Adult / Female / Humans Idioma: En Revista: J Int Med Res Año: 2021 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Graves / Metimazol Límite: Adult / Female / Humans Idioma: En Revista: J Int Med Res Año: 2021 Tipo del documento: Article País de afiliación: Japón